KLK3 and metastatic neoplasm: Although the 2012 US Preventive Services Task Force guidelines recommended against prostate-specific antigen (PSA) screening, this was reversed in 2018, coinciding with shifts in PSA testing practices.1,2 In addition, the adoption of novel positron emission tomography imaging has enabled earlier detection of metastatic disease than conventional bone and computerized tomography scans.2,3